This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Tardive Dyskinesia
and you are
between 18 and 85
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Provided treatments

  • Drug: NBI-98854
  • Drug: NBI-98854
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01733121. The sponsor of the trial is Neurocrine Biosciences and it is looking for 102 volunteers for the current phase.
Official trial title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia